|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Liver fibrosis markers of nonalcoholic steatohepatitis显示文摘Nonalcoholic fatty liver disease(NAFLD) is one of themajor causes of chronic liver injury. NAFLD includes a wide range of clinical conditions from simple steatosis to nonalcoholic steatohepatitis(NASH), advanced fibrosis, and liver cirrhosis. The histological findings of NASH indicate hepatic steatosis and inflammation with characteristic hepatocyte injury(e.g., ballooning degeneration), as is observed in the patients with alcoholic liver disease. NASH is considered to be a potentially health-threatening disease that can progress to cirrhosis. A liver biopsy remains the most reliable diagnostic method to appropriately diagnose NASH, evaluate the severity of liver fibrosis, and determine the prognosis and optimal treatment. However, this invasive technique is associated with several limitations in routine use, and a number of biomarkers have been developed in order to predict the degree of liver fibrosis. In the present article, we review the current status of noninvasive biomarkers available to estimate liver fibrosis in the patients with NASH. We also discuss our recent findings on the use of the glycated albuminto-glycated hemoglobin ratio, which is a new index that correlates to various chronic liver diseases, including NASH. | Hirayuki Enomoto Yukihiro Bando Hideji Nakamura Shuhei Nishiguchi Masafumi Koga | 2015 | World Journal of Gastroenterology2015，21，24： | 12 |
| 2 | Elevation of the glycated albumin to glycated hemoglobin ratio during the progression of hepatitis C virus related liver fibrosis显示文摘AIM: To analyze the relationship between the glycated albumin (GA) to glycated hemoglobin (HbA1c) ratio and the histological grading of liver fibrosis.METHODS: The study retrospectively included consecutive hepatitis C virus positive chronic liver disease patients (n = 142) who had undergone percutaneous liver biopsy between January 2008 and March 2010 at our institution. The ratios of GA/HbA1c were calculated in all patients to investigate the relationship with the degree of the liver fibrosis. The values of the aspartate aminotransferase-to-platelet ratio index (APRI), an excellent marker for the evaluation of liver fibrosis, were also calculated. In addition, we combined the ratio of GA/HbA1c and the APRI in order to improve our ability to detect the presence of significant liver fibrosis. RESULTS: Sixty-one (43%) patients had either no fibrosis or minimal fibrosis (METAVIR score: F0-F1), while 25 (17%) had intermediate fibrosis (F2). Fifty-six (39%) patients had severe fibrosis (F3-F4) and 27 of them had cirrhosis (F4). The mean values of the GA/HbA1c increased with the progression of the fibrosis (F0-1: 2.83 ± 0.24, F2: 2.85 ± 0.24, F3: 2.92 ± 0.35, F4: 3.14 ± 0.54). There was a significant dif- ference between the F0-F1 vs F4, F2 vs F4, and F3 vs F4 groups (P < 0.01, P < 0.01, P < 0.01 and P < 0.05, respectively). The GA/HbA1c ratio was significantly higher in the patients with cirrhosis (F4) than in those without cirrhosis (F0-F3) (3.14 ± 0.54 vs 2.85 ± 0.28, P < 0.0001). The GA/HbA1c ratio was also significantly higher in the patients with severe fibrosis (F3-F4) than in those without severe liver fibrosis (F0-F2) (3.03 ± 0.41 vs 2.84 ± 0.24, P < 0.001). Furthermore, the GA/ HbA1c ratio was also significantly higher in the patients with significant fibrosis (F2-F4) than in those without significant liver fibrosis (F0-F1) (2.98 ± 0.41 vs 2.83 ± 0.24, P < 0.001). The diagnostic performance of the increased GA/HbA1c ratio (> 3.0) was as follows: its sensitivity and specificity for the detection of liver cirrhosis (F4) were 59.3% and 70.4%, respectively and its sensitivity and specificity for the detection of severe liver fibrosis (F3-F4) were 50.0% and 74.4%,respectively. With regard to the detection of significant fibrosis (F2-F4), its sensitivity was 44.4% and its specificity was 77.0%. Although even the excellent marker APRI shows low sensitivity (25.9%) for distinguishing patients with or without significant fibrosis, the combination of the APRI and GA/HbA1c ratio increased the sensitivity up to 42.0%, with only a modest decrease in the specificity (from 90.2% to 83.6%). CONCLUSION: The GA/HbA1c ratio increased in line with the histological severity of liver fibrosis, thus suggesting that this ratio is useful as a supportive index of liver fibrosis. | Nobuhiro Aizawa Hirayuki Enomoto Hiroyasu Imanishi Masaki Saito Yoshinori Iwata Hironori Tanaka Naoto Ikeda Yoshiyuki Sakai Tomoyuki Takashima Takashi Iwai Ei-ichiro Moriwaki Soji Shimomura Hiroko Iijima Hideji Nakamura Shuhei Nishiguchi | 2012 | World Journal of Hepatology2012，4，1： | 10 |
| 3 | Eucalyptone from Eucalyptus globulus显示文摘 | Kenji Osawa Hideyuki Yasuda Hiroshi Morita Koichi Takeya Hideji Itokawa | 1995 | Phytochemistry1995，，1： | 2 |
| 4 | NMR study of the solution structures of the inclusion comple- xes of β - Cyelodextrin with ( + ) - Cateehin and ( - ) - Epieateehin 显示文摘 | Takashi Ishizu Kanako Kintsu Hideji Yamamoto | 1999 | J Phys Chem B1999，103，： | 1 |
| 5 | Triterpenoids of Paeonia Japonica callus tissue显示文摘 | Hideji Itokawa | 1988 | Phytochemistry1988，27，9： | 1 |
| 6 | Development of Earthquake-Resistant, Vibration Control, and Base Isolation Technology for Building Struetures 显示文摘 | Mitsuru Sugisawa Hideji Nakamura Yasushi Lchikawa | 1995 | Nippon Steel Technical Report1995，，66： | 1 |
| 7 | Toshiyuki Akiyama Recent advances in the investigation of eurcuminoids显示文摘 | Hideji Itokawa Qian Shi Toshiyuki Axiyama | 2008 | Chinese Medicine2008，3，： | 1 |
| 8 | Studies on a novel p-coumaroyl glucoside of apigenin and on other flavonoids isolated from Patchouli (Labiatae) 显示文摘 | HIDEJI I KE IICHI S KOICHI T | 1981 | Chem Pharm Bull1981，29，1： | 1 |
| 9 | Isoflavonoids and the other constitunets in callus tissues of pueraria labata显示文摘 | Hideji Itokawa | 1982 | Chem Pharm Bull1982，30，： | 1 |
| 10 | Pregnane glycosides from an antitumour fraction of Periploca sepium 显示文摘 | Hideji I W Xu j P Koichi T | 1988 | Phytochemistry1988，27，4： | 1 |
| 11 | Devel- opment of Earthquake-Resistant, Vibration Control, and for Base Isolation Building Structures 显示文摘 | Mitsuru Suglsawa Hideji Nakamura Yasushi Lchikawa ote | 1995 | Technology NIPPON STEEL TECHNICAL REPORT1995，66，： | 1 |
| 12 | Hepatoma-derived growth factor is a novel prognostic factor for pa- tients with pancreatic cancer 显示文摘 | Hirokazu U Yasuhiko T Hideji N | 2006 | Clin Cancer Res2006，12，20： | 1 |
| 13 | Development of Earthquake-Resistant, Vibration Control, and Base Isolation Technology for Building Structures 显示文摘 | Mitsuru Sugisawa Hideji Nakamura Yasushi Lchikawa | 1995 | Nippon Steel Technical Report1995，66，： | 1 |
| 14 | Development and reliability of a standard rating system for outcome measurement of foot and ankle disorders I: development of standard rating system显示文摘 | Hisateru Niki Haruhito Aoki Suguru Inokuchi Satoru Ozeki Mitsuo Kinoshita Hideji Kura Yasuhito Tanaka Masahiko Noguchi Shigeharu Nomura Masahito Hatori Shinobu Tatsunami | 2005 | Journal of Orthopaedic Science2005，，5： | 1 |
| 15 | Studies on a novel p-Coumaroyl glacoside of apigenin and on other flavonoids isolated from Patchouli(Labiatae) 显示文摘 | HIDEJI I KEIICHI S KOICHI T | 1981 | Pharm Soc Jap1981，29，1： | 1 |
| 16 | Pseudostellarins A -C,new tyrosinase inhibitory cyclic peptides from Pseudostellaria Heterophylla显示文摘 | Hiroshi M Takashi K Hideyuki K Hideji I | 1994 | Phytochemistry1994，50，： | 1 |
| 17 | Diarylheptanoids from the rhizome of Alpinia offwinarum Hance 显示文摘 | Hideji I Hirosi M Ikuko M et a/ | 1985 | Chem Pharm Bull1985，33，11： | 1 |
| 18 | Development of earthquake resistant, vibration control, and base isolation technology for building structures 显示文摘 | Mitsuru Sugisawa Hideji Nakamura Yasushi Lchikawa | 1995 | Nippon Steel Technical Report1995，66，： | 1 |
| 19 | Immobilization of penicillin acylase using porous polyacrylonitrile fibers 显示文摘 | FUMIHIRO I HIDEJI S | 1991 | J Ferment Bioeng1991，71，2： | 1 |
| 20 | Cajucarins A and B,new clerodane diterpenes from croton cajucara,and their conformations显示文摘 | HIDEJI I YOSHITATSU I MASAHIRO S | 1990 | Chem Pharm Bull1990，38，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员